Foghorn Therapeutics

Novel BRG1BRM Inhibitor in Metastatic Uveal Melanoma Shows Safety and Preliminary Efficacy | Pharmtales

Novel BRG1/BRM Inhibitor in Metastatic Uveal Melanoma Shows Safety and Preliminary Efficacy

SG Tylor

Source – Foghorn Therapeutics Foghorn Therapeutics has highlighted the safety and tolerability of FHD-286 in metastatic uveal melanoma (mUM) through ...